Intervention of CAR-T Against Cervical Cancer

NCT ID: NCT03356795

Last Updated: 2019-09-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-15
• Study Completion Date: 2020-12-31

Brief Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Detailed Description

Cervical cancer is a cancer arising from the cervix. Human papillomavirus (HPV) infection causes more than 90% of cases. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Worldwide, cervical cancer is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women. The treatment of cervical cancer consists of surgical intervention, radiation, chemotherapy and immunotherapy.

In this study, the participant's T-cells will be collected and modified. Then the modified T cells, called chimeric antigen receptor modified-T cells (CAR T) which can recognize specific molecules that are expressed on the surface of cervical cancer cells, are given back to the participant by intravenous infusion.

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Conditions

Cervical Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cervical cancer-specific CAR-T cells

Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.

Group Type: EXPERIMENTAL

Cervical cancer-specific CAR-T cells

Intervention Type: BIOLOGICAL

1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV

Interventions

Cervical cancer-specific CAR-T cells

1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Patients with stage III, IV or relapsed cervical cancer confirmed by histology and biopsy.

2. Age: ≥ 18 years and ≤ 70 years.

3. 4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy.

4. Side Effects of Chemotherapy have subsided.

5. GD2, PSMA, Muc1, Mesothelin or other markers is expressed high (above 2+) in malignancy tissues by immuno-histochemical or flow cytometry.

6. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.

7. Expected survival ≥ 12 weeks.

8. Initial hematopoietic reconstitution with

• neutrophils (ANC) ≥ 1×10^6/L;
• platelet (PLT) ≥ 1×10^8/L.

9. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with

• serum creatinine ≤ 2×ULN;
• serum bilirubin ≤ 3×ULN;
• AST/ALT ≤ 2.5×ULN.

10. Oxygen saturation ≥ 90%.

11. Written, informed consent obtained prior to any study-specific procedures.

Exclusion Criteria

1. Airway obstruction caused by tumor.

2. History of epilepsy or other central nervous system diseases.

3. Patients who require systemic corticosteroid or other immunosuppressive therapy.

4. History of prolonged or serious heart disease during QT.

5. history of serious cyclophosphamide toxicity.

6. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.

7. Inadequate liver and renal function with

• serum creatinine > 1.5 mg/dl;
• serum (total) bilirubin > 2.0 mg/dl;
• AST & ALT > 3 x ULN.

8. Pregnant or lactating females.

9. Serious active infection during screening.

10. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.

11. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Shenzhen Geno-Immune Medical Institute

OTHER

Sponsor Role: lead

Responsible Party

Lung-Ji Chang

President

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lung-Ji Chang, PhD

Role: PRINCIPAL_INVESTIGATOR

Shenzhen Geno-Immune Medical Institute

Locations

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lung-Ji Chang, PhD

Role: CONTACT

c@szgimi.org

86-075586725195

Facility Contacts

Lung-Ji Chang, PhD

Role: primary

c@szgimi.org

86-075586725195

Other Identifiers

GIMI-IRB-17017

Identifier Type: -

Identifier Source: org_study_id